MedTrace Logo

Antipsychotics and Gene Expression in Soft Tissues

NCT01185743 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2017-03-23

No results posted yet for this study

Summary

Schizophrenia is a severe chronic and disabling mental disorder and is associated with a significant reduction in life expectancy. Atypical antipsychotic treatment compliance may be jeopardized because of drug induced weight gain and abnormalities in carbohydrate and lipid metabolism.

Aim: to gain data on drug related effects on gene expression and regulation with special regard to glucose metabolism.

Conditions

Interventions

DRUG

olanzapine

olanzapine 10mg od + placebo od

DRUG

ziprasidone

ziprasidone 40mg td

DRUG

placebo

placebo td

Sponsors & Collaborators

  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Martin Brunner, MD · Medical University of Vienna

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2017-01-01
Completion
2017-01-01

Countries

  • Austria

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01185743 on ClinicalTrials.gov